Ask AI
ProCE Banner Activity

The Evolving CRSwNP Treatment Landscape: Emerging Targeted Biologic Therapies and What Lies Ahead

Clinical Thought

After understanding the type 2 inflammatory pathway associated with many chronic rhinosinusitis with nasal polyps (CRSwNP) cases, learn how surgery and biologic therapies should be used to help patients with CRSwNP achieve disease control.

Released: November 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Snot Force Alliance, Inc.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Partners

Snot Force Alliance, Inc.

ProCE Banner

Disclosure

Primary Author

Thomas S. Higgins, MD, MSPH, MBA: consultant/advisor/speaker: Medtronic, Optinose, Regeneron/Sanofi, SpirAir, Stryker.